4
Tetrahedron
When the methyl ester 10k was subjected to the same
the prepared compounds can find some applications in solid-state
organic electronics.
reaction conditions, oxazolone 9 was obtained in 95% yield
(Table 2). A similar result was obtained for the reaction between
10k and T3P®, affording 9 in 81% yield, which is a structural
isomer of 4-(3-chlorobenzylidene)-2-phenyl-1,3-oxazol-5(4H)-
one, a compound with reported antimicrobial activity.21
Acknowledgments
We would like to thank DGAPA-UNAM for financial support
(Grant IN212513), M. A. Almaraz-Girón thanks CONACYT for
scholarship (Grant 217555/208278), Simón Hernández-Ortega
for X-Ray structure elucidation, Margarita Guzmán Villanueva
and R. C. Cañas-Alonso for HRMS data and Marisela Gutierrez
Franco for IR spectra.
Discriminating between the structures of oxazolimines and
imidazolones proved to be spectroscopically challenging, as can
also be intuited from literature reports on the synthesis of this
kind of compounds. Fortunately, we were able to obtain crystals,
and the structure of 4-benzylidene-oxazol-5(4H)-imine was
unequivocally assigned through single-crystal X-ray diffraction
studies.
References
1. Stevenson, L.; Pimlott, S. L.; Sutherland, A. Tetrahedron Letters
2007, 48, 7137–7139.
2. Liu, Z. Z.; Tang, Y. F.; Chen, S. Z. Chines. Chem. Lett. 2001, 12,
947–950.
Single crystals suitable for X-ray diffraction (SXRD) were
obtained for compounds 3a, 3d and 3e and solved in the P 21/C,
P 21/C and P-1 space groups, respectively. Crystals were
obtained from DMSO solutions in a NMR tube (a drop of water
was added) of the corresponding products in solvent-free
packing. Sec-butyl groups were disordered, and were refined and
modeled in two contributions using variable site occupational
factor, SOF, with a 0.75/0.25 ratio. All compounds feature the
oxazol-imine moiety, as can be appreciated in the crystal
structures in Figure 2.
3. Whaley, W. M.; Govindachari, T. R. In Organic Reactions; John
Wiley & Sons, Inc., 2012.
4. Gong, X.; Yang, H.; Liu, H.; Jiang, Y.; Zhao, Y.; Fu, H. Org. Lett.
2010, 12, 3128–3131.
5. Yu, Y.; Ostresh, J. M.; Houghten, R. A. J. Comb. Chem. 2001, 3,
521–523.
6. Gabillet, S.; Loreau, O.; Specklin, S.; Rasalofonjatovo, E.; Taran,
F. J. Org. Chem. 2014, 79, 9894–9898.
7. Boyd, G. V.; Wright, P. H. J. Chem. Soc., Perkin Trans. 1 1972,
Interestingly, the π-conjugated system in 3d presents periodic
stacking in the crystalline phase (Figure 3). This feature has been
considered a desirable property, since it favors carrier mobility in
organic electronic devices, such as field-effect transistors, which
makes this compound a potentially interesting material for solid
state applications.22
1140–1143.
8. Sun, Y.; Martell, A. E.; Welch, M. J. Tetrahedron 2000, 56, 5093–
5103.
9. Rudrapal, M.; Satyanandam, R. S.; Swaroopini, T. S.; Lakshmi, T.
N.; Jaha, S. K.; Zaheera, S. Med Chem Res 2013, 22, 2840–2846.
10. Corey, E. J.; Enders, D. Tetrahedron Letters 1976, 17, 3–6.
11. Esmaeili, A. A.; Shahmansouri, S.; Habibi, A.; Fakhari, A. R.
Tetrahedron 2012, 68, 8046–8051.
12. (a) Dabholkar, V. V.; Karekar, A.; Naik, P.; Shinde, N. B.
Heterocyc. Lett. 2012, 2, 405–410; (b) Dabholkar, V. V.; Syed, S.
A. S. A. Rasayan J. Chem. 2012, 3, 761–765.
13. (a) Sharada, L. N.; Aparna, Y.; Saba, N.; Sunitha, S. N. T.;
Viveka, L. International Journal of Scientific and Research
Publications, 2015, 5, 1–9; (b) Bhusare, S. R.; Shekapure, J. L.;
Pawar, R. P.; Vibhute, Y. B.; Bhawal B. M. Chemistry of
Heterocyclic Compounds, 2003, 39, 726–728; (c) Fisk, J. S.;
Mosey, R. A.; Tepe, J. J. Chem. Soc. Rev. 2007, 36, 1432–1440;
(d) Youssef, A. S. A.; Kandeel, K. A.; Abou-Elmagd, W. S. I.;
Haneen, D. S. A. J. Heterocyclic Chem. 2015, 53, 175–182.
14. Jursic, B. S.; Sagiraju, S.; Ancalade, D. K.; Clark, T.; Stevens, E.
D. Synthetic Communications 2007, 37, 1709–1714.
15. (a) You, Y.; He, Y.; Burrows, P. E.; Forrest, S. R.; Petasis, N. A.;
Thompson, M. E. Adv. Mater. 2000, 12, 1678–1681; (b) Joshi, H.;
Upadhyay, P.; Karia, D.; Baxi, A. J. European Journal of
Medicinal Chemistry 2003, 38, 837–840; (c) Saravanan, S.;
Selvan, P. S.; Gopal, N.; Gupta, J. K.; De, B. Arch. Pharm. Chem.
Life Sci. 2005, 338, 488–492.
16. Baldwin, J. E. J. Chem. Soc., Chem. Commun. 1976, 734–736.
17. Fodor, G.; Nagubandi, S. Tetrahedron 1980, 36, 1279–1300.
18. (a) Zewge, D.; Chen, C.; Deer, C.; Dormer, P. G.; Hughes, D. L. J.
Org. Chem. 2007, 72, 4276–4279; (b) Eaton, P. E.; Carlson, G. R.;
Lee, J. T. J. Org. Chem. 1973, 38, 4071–4073.
19. Whaley, W. M.; Govindachari, T. R. Org. React. 1951, 6, 74–150;
(b) Doi, S.; Shirai, N.; Sato, Y. J. Chem. Soc., Perkin Trans. 1,
1997, 2217–2221; (c) Wang, X.; Tan, J.; Grozinger, K.
Tetrahedron Lett. 1998, 39, 6609–6612.
Figure 3. Crystal packing for 3d, illustrating the periodic π -
stacking displayed in the solid state.
3. Conclusions
We have developed a one-pot synthetic methodology for the
easy preparation of 4-benzylidene-2-aryl-1,3-oxazol-5-(4H)-
imines starting from phenyl pyruvic acid and aryl amides. The
same compounds can be obtained from α,β-unsaturated acid
derivatives, with a significant increase in overall yield. The
developed methodology can also be used for the preparation of
other α,β-unsaturated acid derivatives with moderate to good
yields. Both procedures are based on the in situ formation of an
oxazolone as intermediate. Even though the structural
discrimination between benzylidene-2-aryl-1,3-oxazol-5-(4H)-
imines and benzylidene-1H-imidazol-5(4H)-ones is not straight
forward, we were able to unambiguously confirm the structure of
the benzylidene-2-aryl-1,3-oxazol-5-(4H)-imines obtained in this
work using single-crystal X-ray diffraction studies.
20. Ábrányi-Balogh, P.; Földesi, T.; Grün, A.; Volk, B.; Keglevich,
G.; Milen, M. Tetrahedron Lett. 2016, 57, 1953-1957.
21. Bala, S.; Saini, M.; Kamboj, S. Int. J. ChemTech Res. 2011, 3,
1102–1118.
22. H. Moon, R. Zeis, E. J. Borkent, C. Besnard, A. J. Lovinger, T.
Siegrist, C. Kloc, Z. N. Bao, J. Am. Chem. Soc. 2004, 126, 15322–
15323.
Compound 3a can be considered as a structural analog of
PK11195 and might show similar bioactivity. We believe that the
proposed methodology can be used to prepare bioactive
compounds with different molecular complexities. Additionally,
Supplementary Material
Supplementary data associated with this article can be found,
in the online version, at